Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 39798151 · doi:10.1093/nutrit/nuae203
What was done
A systematic review and meta-analysis across four databases (PubMed, Embase, Scopus, and Cochrane Collaboration Library) assessed the efficacy of palmitoylethanolamide (PEA) in pain management across nociceptive, neuropathic, and nociplastic pain conditions. Randomized clinical trials reporting pain and quality of life were analyzed using standardized mean differences (SMD) and heterogeneity statistics (χ2 and I2) across 18 studies totaling 1,196 patients (PROSPERO CRD42024550546).
What was found
Pain was significantly reduced in the PEA group at 6 weeks (SMD, -0.90; 95% CI, -1.60 to -0.31), 8 weeks (SMD, -0.98; 95% CI, -1.61 to -0.36), and 24–26 weeks (SMD, -1.16; 95% CI, -2.15 to -0.17). Quality of life improved significantly with PEA overall (SMD, -0.61; 95% CI, -0.93 to -0.30), with differences at 4 weeks (SMD, -0.36; 95% CI, -0.65 to -0.07) and 8 weeks (SMD, -0.66; 95% CI, -1.15 to -0.17). PEA was effective across all evaluated pain types: nociceptive (SMD, -0.74; 95% CI, -1.42 to -0.06), neuropathic (SMD, -0.97; 95% CI, -1.54 to -0.39), and nociplastic (SMD, -0.59; 95% CI, -1.15 to -0.03).
Why it matters
This meta-analysis consolidates randomized trial evidence demonstrating that PEA reduces pain and improves quality of life across multiple chronic pain types, supporting its evaluation as a non-opioid pain intervention.
Limits
The total sample size was modest (1,196 patients across 18 trials, averaging ~66 participants per trial), and wide confidence intervals reflect substantial variance between studies. The abstract does not provide exact I2 heterogeneity values, specific PEA dosing, formulation details (e.g., micronized vs. standard), comparator types, or adverse event data.
Cited by
- supports Palmitoylethanolamide (PEA) stabilizes mast cells, is present in human breast milk, and possesses analgesic and anti-inflammatory properties.
- supports Palmitoylethanolamide (PEA) relieves pain and reduces inflammation following an injury.